Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. patient positioner
Show results for

Refine by

Patient Positioner Articles & Analysis

80 news found

Enhancing Ergonomics for Dentists and Surgeons: Promoting Health, Efficiency, and Career Longevity

Enhancing Ergonomics for Dentists and Surgeons: Promoting Health, Efficiency, and Career Longevity

Summary Dentists and surgeons devote their professional lives to improving patient health, often engaging in complex procedures that require precision, concentration, and prolonged static or awkward positioning. However, inadequate ergonomics can result in chronic pain, musculoskeletal disorders (MSDs), fatigue, and shortened careers, with studies indicating that up to 80% of these professionals ...

BySurgiTel is a Division of General Scientific Corporation (GSC)


A Phase Ii Trial Of Onapristone In Combination With Fulvestrant For Patients With Er-Positive And Her2-Negative Metastatic Breast Cancer After Progression On Endocrine Therapy And Cdk 4/6 Inhibitors

A Phase Ii Trial Of Onapristone In Combination With Fulvestrant For Patients With Er-Positive And Her2-Negative Metastatic Breast Cancer After Progression On Endocrine Therapy And Cdk 4/6 Inhibitors

Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. SMILE STUDY is a multi-institutional phase II clinical trial to determine the efficacy of an antiprogestin, Onapristone +fulvestrantas second line therapy for patients with HR+/HER2- metastatic breast cancer (MBC). Hypothesis: The ...

ByContext Therapeutics Inc.


Perimeter Medical Imaging AI Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of Wide-Field Optical Coherence Tomography (WF-OCT) in Head and Neck Surgeries

Perimeter Medical Imaging AI Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of Wide-Field Optical Coherence Tomography (WF-OCT) in Head and Neck Surgeries

Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) announced the publication of a peer-reviewed research article in JAMA Otolaryngology—Head and Neck Surgery. The study’s findings validate the further exploration of the use of Perimeter’s wide-field Optical Coherence Tomography (WF-OCT) technology to ...

ByPerimeter Medical Imaging AI


Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant’s PFS Increases with Duration of Prior CDK4/6i in ER+, HER2- in Metastatic Setting

Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant’s PFS Increases with Duration of Prior CDK4/6i in ER+, HER2- in Metastatic Setting

Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of care as a ...

ByThe Menarini Group


Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema

Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices Agency (PMDA). ...

ByPulmonx Corporation


Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting

Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting

Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRPα monoclonal antibody ES004, PD-L1/SIRPα bispecific antibody ...

ByElpiscience


New Research Confirms that Zio by iRhythm Provides High Value From a Health Economic Perspective

New Research Confirms that Zio by iRhythm Provides High Value From a Health Economic Perspective

iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that detect, predict, and prevent disease, today announced a new health economic analysis of the mSToPS study, presented at the American Heart Association’s 2022 Scientific Sessions event. The study, titled “Cost-Effectiveness ...

ByZio by iRhythm Technologies, Inc.


Evolution of ePROM: Advancements, Concerns, and the Way Forward

Evolution of ePROM: Advancements, Concerns, and the Way Forward

Patients’ directly reported outcomes in certain rare and chronic diseases are considered reliable for understanding the disease’s natural history, palliative treatments that focus primarily on symptom control, and quality of life. Electronic Patient-Reported Outcome Measures (ePROMs) are now allowing these patients to self-report health conditions and treatment effectiveness ...

ByJeeva Informatics Solutions Inc.


Analysis supporting treatment with Diamyd published in peer-reviewed scientific journal

Analysis supporting treatment with Diamyd published in peer-reviewed scientific journal

An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). As communicated on 23 September 2021, ...

ByDiamyd Medical AB


Updated results from clinical trial with Diamyd presented today at diabetes conference

Updated results from clinical trial with Diamyd presented today at diabetes conference

Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd® in individuals diagnosed with Latent Autoimmune Diabetes in Adults (LADA) were presented today at the European Association for the Study of Diabetes (EASD) conference in Stockholm, Sweden. The updated ...

ByDiamyd Medical AB


CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society (ERS) International Conference. Data on the first 40 patients in the study demonstrated that treatment with the AeriSeal System successfully converted the ...

ByPulmonx Corporation


Cellworks Singula TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies

Cellworks Singula TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies

Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-024-04 study, which demonstrate that the Cellworks SingulaTM Therapy Response Index (TRI) was strongly predictive of Overall Survival (OS) and Progression-Free Survival (PFS) for newly diagnosed Glioblastoma Multiforme (GBM) patients. In ...

ByCellworks Research India Private Limited


Cellworks Singula TRI Predicts Personalized Treatment Outcomes for Esophageal Adenocarcinoma Patients Beyond Standard Clinical Factors

Cellworks Singula TRI Predicts Personalized Treatment Outcomes for Esophageal Adenocarcinoma Patients Beyond Standard Clinical Factors

Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-004 study, which demonstrate that the Cellworks SingulaTM Therapy Response Index (TRI) is highly predictive of Overall Survival (OS), Disease-Free Survival (DFS) and Mandard-tumor regression grade (TRG) for gastroesophageal adenocarcinoma ...

ByCellworks Research India Private Limited


Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis ...

ByGalera Therapeutics, Inc.


Excite Medical displays the DRX9000 at the Wave 2019

Excite Medical displays the DRX9000 at the Wave 2019

Excite Medical, the leading provider of non-surgical spinal decompression machines, announced that they will participate in the upcoming WAVE Convention and Expo held at the Oakland Marriot City Center in Oakland, CA starting on August 16th. As an exhibitor, Excite Medical will present their flagship product, the DRX9000® non-surgical spinal decompression machine in front of over 2000 ...

ByExcite Medical Corp.


Cost Effectiveness of MRI for Early Detection of Prostate Cancer

Cost Effectiveness of MRI for Early Detection of Prostate Cancer

Prostate cancer is the second most common and lethal cancer among men in the United States. In 2021, an estimated 250,000 men were diagnosed, with the majority over 65 years old. During the height of the pandemic, diagnosis and screening numbers plummeted, resulting in thousands of missed diagnoses. Lost in the surgical backlog, already delayed diagnoses may be further delayed, potentially ...

ByFocal Healthcare


Regor announces China NMPA approval of the IND for RGT-419B capsule, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer

Regor announces China NMPA approval of the IND for RGT-419B capsule, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer

Regor Therapeutics Group announced that the investigational new drug (IND) application of RGT-419B capsule, a CDK2/4/6 small molecule inhibitor, had been approved by the National Medical Products Administration (NMPA) of China. A Phase I clinical study will be conducted in Chinese patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) ...

ByRegor Pharmaceuticals Inc.


eCential Robotics boosts its platform technology with a surgical robotic arm

eCential Robotics boosts its platform technology with a surgical robotic arm

Gières (Grenoble), France, June 17, 2021 - eCential Robotics, a French growth company that designs, manufactures and markets the first unified 2D/3D robotic imaging and surgical navigation system for bone surgery indications, unveiled its surgical robotic arm as a world premiere at the annual meeting of the French Society of Spinal Surgery (SFCR), which is being held from June 17 to ...

ByeCential Robotics


Signifier Medical Technologies Announces $49MM Purchase of Existing Shares by Waha Capital, Angelus Sano Ventures and Segulah Medical Acceleration

Signifier Medical Technologies Announces $49MM Purchase of Existing Shares by Waha Capital, Angelus Sano Ventures and Segulah Medical Acceleration

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announced that Waha Capital PJSC (“Waha Capital”), Angelus Sano Fund L.P. (“Angelus”), Segulah Medical Acceleration AB (“Segulah Medical”) and certain other individual investors have collectively invested approximately $49 ...

BySignifier Medical Technologies Ltd


TriMedika Wins Innovate UK Women in Innovation Awards

TriMedika Wins Innovate UK Women in Innovation Awards

Dr. Roisin Molloy, CEO, and co-founder of TriMedika; an innovative medical technology manufacturer, supplying the most accurate hospital-grade non-contact thermometers to hospitals worldwide, based in Belfast. Innovate UK launched Women in Innovation in 2016, after research revealed that just 1 in 7 applications for Innovate UK support came from women. Boosting the number of female entrepreneurs ...

ByTriMedika

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT